



DAFTAR PUSTAKA

1. Akib A, Soepriadi M, Setiawan B. Buku Ajar Alergi Immunologi Anak. Jakarta: Badan Penerbit Ikatan Dokter Anak Indonesia; 2011. pp 345–372.
2. Mina R, Brunner H. Are there differences in presentation, genetics, response to therapy, damage accrual compared to adult lupus? *Rheum Dis Clin North Am.* 2010;36–41.
3. Weiss J. Pediatric Systemic Lupus Erythematosus : More Than a Positive Antinuclear Antibody. *Pediatr Rev.* 2012;33:62–74.
4. Bertias G, Cervera R, Boumpas DT. Systemic lupus erythematosus: pathogenesis and clinical features. *Eular On-line Course Rheum Dis.* 2012;476–505.
5. Sumadiono, Satria CD, Fakhirah S. Profil penyakit rematik dan tindakan injeksi sendi pada anak di RSUP dr. Sardjito Yogyakarta. In: *Proceedings of the 9th Winaya Waidya Anarawata (WWA) Conference, Nov 10-11, IDAI, Yogyakarta.* Yogyakarta; 2018.
6. Kamphuis S, Silverman E. Prevalence and burden of pediatric-onset systemic lupus erythematosus. *Nat Rev Rheumatol.* 2010;6:538–46.
7. Demircin G. An Update on Treatment and Outcome of Lupus Nephritis in Children. *Ann Pediatr Rheumatol.* 2013;2:99–106.
8. Mok C. Understanding lupus nephritis: diagnosis, management, and treatment options. *Int J Women's Heal.* 2012;4:213–22.
9. Kuhn A, Bonsmann G, Joachim H, Herzer P, Tenbrock K, Schneider M. The Diagnosis and Treatment of Systemic Lupus Erythematosus. *Dtsch Arztebl Int.* 2015;112:423–32.
10. Turchetti G, Yazdany J, Palla I, Yelin E, Mosca M. Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider. *Clin Exp Rheumatol.* 2012;30:1–7.
11. Meller S, Homey B, Ruzicka T. Socioeconomic factors in lupus erythematosus. *Autoimmun Rev.* 2005;4:242–6.
12. Ormsby K. Pediatric Sytemic Lupus Nephritis: Current Research in Treatment and Outcomes. Dissertation. Washington State University, United States of America, 2012.
13. Levy D, Kamphuis S. Systemic lupus erythematosus in children and adolescents. *Pediatr Rev.* 2012;59:345–64.
14. Mina R, Brunner HI. Pediatric lupus- Are there differences in presentation, genetics, response to therapy, damage accrual compared to adult. *Rheum Dis Clin North Am.* 2010;36:53–80.
15. Kasjmir Y, Handoyo K, Wijaya L. Diagnosis dan pengelolaan lupus eritematosus sistemik. *Perhimpun Rheumatol Indones.* 2011;1–45.
16. Tan E, Cohen A, Fries J, Masi A, McShane D, Rothfield N. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum.* 1982;1271–7.



17. Hochberg M. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum.* 1997;40:1725–33.
18. Hahn B, McMahon M, Wilkinson A, Wallace W, Daikh D, Fitzgerald J. American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis. *Am Coll Rheumatol.* 2012;64:797–808.
19. Hahn BH, Mahon MAMC, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology Guidelines for Screening , Treatment , and Management of Lupus Nephritis. *Arthritis Care Reseach.* 2012;64:797–808.
20. Kuhn A, Bonsmann G, Anders H, Herzer P, Tenbrock K, Schneider M. The Diagnosis and Treatment of Systemic Lupus Erythematosus. *Dtsch Ärzteblatt Int.* 2015;112:423–32.
21. Mina R, Scheven V, Ardoin S, Eberhard A, Punaro M, Ilowite N. Consensus Treatment Plans for Induction Therapy of Newly Diagnosed Proliferative Lupus Nephritis in Juvenile Systemic Lupus Erythematosus. *Am Coll Rheumatol.* 2012;64:375–83.
22. Bomback AS, Appel GB. Updates on the Treatment of Lupus Nephritis. *J Am Soc Nephrol.* 2010;21:2028–35.
23. Lateef A, Petri M. Unmet medical needs in systemic lupus erythematosus. *Arthritis Res Ther.* 2012;14.
24. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. *Arthritis Rheum.* 2006;54:2550–7.
25. Lee PPW, Lee T, Ho MH, Wong WHS, Lau Y. Recurrent major infections in juvenile-onset systemic lupus erythematosus — a close link with long-term disease damage. *Rheumatology.* 2007;1290–6.
26. García-carrasco M, Mendoza-pinto C, Escárcega RO, Jiménez-hernández M, Etchegaray I, Pt M, et al. Osteoporosis in Patients with Systemic Lupus Erythematosus. 2009;11:486–91.
27. Lam G, Petri M. Assessment of systemic lupus erythematosus. *Clin Exp Rheumatol.* 2005;23:120–32.
28. Iaccarino L, Larosa M. *Connective Tissue Disease.* Springer Int Publ. 2016;1:199–211.
29. Luca Iaccarino, Maddalena Larosa AD. *Connective Tissue Disease.* Roccatello D, Emmi L, editors. *Connective Tissue Disease: A Comprehensive Guide-Volume 1.* Cham: Springer International Publishing, 2016. pp. 55–81.
30. Carrasco M, Pinto C, Escarcega R, Hernandez J. Osteoporosis in Patients with Systemic Lupus Erythematosus. 2009;11:486–91.
31. Smith EMD, Foster HE, Beresford MW. Adding to complexity: Comorbidity in paediatric rheumatic disease. *Rheumatol.* 2013;52:22–33.
32. Smith EMD, Foster H, Beresford MW. Comorbidity in paediatric rheumatic disease. *Rheumatology.* 2013;52:22–33.



33. Wong S, Lee T, Lee K, Chim S. Lupus nephritis in Chinese children-a territory-wide cohort study in Hongkong. *Pediatr Nephrol*. 2006;8:1104–12.
34. Morris J, Putterman C. Gender Differences in the Pathogenesis and Outcome of Lupus and of Lupus Nephritis. *Clinical and developmental immunology*. 2002;10.
35. Cervera R, Eispinosa G, Cruz D. Systemic Lupus Erythematosus: Pathogenesis, clinical manifestations, and diagnosis. *Eular Course Rheum Dis*. 2009;17.
36. Sequeira J, Keser G, Greenstein B. Systemic lupus erythematosus: sex hormones in male patients. 1993;2:315–7.
37. McMurry R, May W. Sex hormones and systemic lupus erythematosus. *Arthritis Rheum*. 2003;48:2000–10.
38. Hernandez-Cruz B, Tapia N, Villa-Romero AR, Reyes E, Cardiel MH. Risk factors associated with mortality in systemic lupus erythematosus. A case-control study in a tertiary care center in Mexico City. *Clin Exp Rheumatol*. 2001;19:395–401.
39. Mok C, Lau CS. Pathogenesis of systemic lupus erythematosus. *J Clin Pathol*. 2003;56:481–90.
40. Manson J, Isenberg D. The Pathogenesis of systemic lupus erythematosus. *J Netherl Med*. 2003;61:343–6.
41. Moon SJ, Kwok SK, Ju JH, Park KS, Park SH, Cho CS, et al. Predictors of chronic kidney disease in Korean patients with lupus nephritis. *J Rheumatol*. 2011;38:2588–97.
42. Hanako S, Djuhaeni H, Setiabudiawan B, Sunjaya D, Mutyara K, Rinawan F. Kepatuhan Minum Obat Pada Pasien Lupus Eritematosus Sistemik di RSUP Dr. Hasan Sadikin Bandung. *Maj Kedokt Bandung*. 2018;50:21–8.
43. Brunner HI, Holland M, Beresford MW, Ardoin SP, Appenzeller S, Silva CA, et al. American College of Rheumatology Provisional Criteria for Global Flares in Childhood-Onset Systemic Lupus Erythematosus. *Arthritis Care Res*. 2018;70:813–22.
44. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response C. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. *Arthritis Rheum*. 2006;54:421–32.
45. Zonana-Nacach A, Yañez P, Jiménez-Balderas FJ, Camargo-Coronel A. Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus. *Lupus*. 2007;16:997–1000.
46. Wang LC, Yang YH, Lu MY, Chiang BL. Retrospective analysis of the renal outcome of pediatric lupus nephritis. *Clin Rheumatol*. 2004;23:318–23.
47. Korbet SM, Lewis EJ. Complete remission in severe lupus nephritis : assessing the rate of loss in proteinuria. *Nephrol Dial Transpl*. 2012;27:2813–9.
48. Moroni G, Raffiotta F, Ponticelli C. Remission and withdrawal of therapy in lupus nephritis. *J Nephrol*. 2016;29:559–65.
49. Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, et al. Predictors and Outcome of Renal Flares After Successful Cyclophosphamide Treatment for Diffuse



- Proliferative Lupus Glomerulonephritis. *Arthritis Rheum.* 2004;50:2559–68.
50. Luna JDD, Tallada M, Marti A, Mario J. Urinary tract infections and lupus erythematosus. *Ann Rheum Dis.* 2004;63:431–7.
 51. Taylor EB, Ryan MJ. Understanding mechanisms of hypertension in systemic lupus erythematosus. *Ther Adv Cardiovasc Dis.* 2017;11:20–32.
 52. Sekarwana N, Rachmadi D, Hilmanto D. *Konsensus Tata Laksana Hipertensi pada Anak.* Jakarta: Ikatan Dokter Anak Indonesia; 2016. 1–15 p.
 53. Hahn BH, McMahon M, Wilkinson A, Wallace WD, Daikh DI, FitzGerald J, et al. American College of Rheumatology Guidelines for Screening, Case Definition, Treatment and Management of Lupus Nephritis. *Arthritis Care Res.* 2013;64:797–808.
 54. Sprangers B, Monahan M, Appel GB. Diagnosis and treatment of lupus nephritis flares - An update. *Nat Rev Nephrol [Internet].* 2012;8:709–17. Available from: <http://dx.doi.org/10.1038/nrneph.2012.220>
 55. Costenbader K, Khamashta M, Garcia SR, Rodriguez MTP, Petri M, Elliott J, et al. Development and Initial Validation of the Self-Assessed Lupus Damage Index Questionnaire (LDIQ). *Arthritis Care Res.* 2010;62:559–68.
 56. Petri M, Purvey S, Fang H, Magder LS. Predictors of organ damage in systemic lupus erythematosus: The Hopkins Lupus Cohort. *Arthritis Rheum.* 2012;64:4021–8.
 57. Ogila K, Aduol O. Protection of Cyclophosphamide Induced Myelosuppression by Extracts of *Asparagus setaceus* Kunth and *Caesalpinia volkensii* Harm in Albino Rats. *Int J Pharm Pharmacol.* 2017;1:114–29.
 58. Schmajuk G, Yazdany J. Drug Monitoring in Systemic Lupus Erythematosus: A Systematic Review. *Semin Arthritis Rheum.* 2011;40:559–75.
 59. Hartgens F, Rietjens G, Keizer H, Kuipers H, Wolffenbuttel B. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein. *Br J Sport Med.* 2004;38:253–9.
 60. Stanbury R, Graham E. Systemic corticosteroid therapy—side effects and their management. *Br J Ophthalmol.* 1998;702–8.
 61. Aparicio Soto M, Sanchez Hidalgo C, Alarcon De La Lastra. An update on diet and nutritional factors in systemic lupus erythematosus management. *Nutr Res Rev.* 2017;30:118–37.
 62. Lakshmi N, Peterson M, Hassett M, Lehman A, JA T. Improving quality of life assessment in children with systemic lupus erythematosus. *Int J Clin Rheumatol.* 2017;7:229–35.
 63. Knight A, Weiss P, Morales K, Gerdes M, Gutstein A, Vickery M, et al. Depression and anxiety and their association with healthcare utilization in pediatric lupus and mixed connective tissue disease patients: A cross-sectional study. *Pediatr Rheumatol.* 2014;12:1–12.
 64. Bohmat L, Bessonova I, Shevchenko N, Akhnazariants E, Holovko T. Comorbidity Index in Children with Systemic Lupus Erythematosus. *Paediatr Rheumatol.* 2019;78:1988–9.
 65. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus.



Curr Opin Rheumatol. 2001;13:345–51.

66. Teh CL, Ling GR. Causes and predictors of mortality in hospitalized lupus patient in Sarawak General Hospital, Malaysia. *Lupus*. 2013;22:106–11.